Active Pharmaceutical Ingredients (API)

Active Pharmaceutical Ingredients (API)

Global Active Pharmaceutical Ingredients (API) Market to Reach $264.1 Billion by 2027

In the changed post COVID-19 business landscape, the global market for Active Pharmaceutical Ingredients (API) estimated at US$176.1 Billion in the year 2020, is projected to reach a revised size of US$264.1 Billion by 2027, growing at aCAGR of 6% over the period 2020-2027. Innovative, one of the segments analyzed in the report, is projected to record 5.7% CAGR and reach US$180.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Generic segment is readjusted to a revised 6.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $61 Billion, While China is Forecast to Grow at 6.2% CAGR

The Active Pharmaceutical Ingredients (API) market in the U.S. is estimated at US$61 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$42 Billion by the year 2027 trailing a CAGR of 6.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.3% and 5.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.

Select Competitors (Total 266 Featured) -

  • AbbVie Inc.
  • Aurobindo Pharma Ltd.
  • BASF SE
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Lupin Ltd.
  • Merck KGaA
  • Novartis International AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
Year 2021 in Review and Near-term Outlook
Prolonged Pandemic, Ukraine-Russia Conflict and Ensuing Economic Disruptions Impact Growth Outlook
EXHIBIT 1: World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2021, 2022 and 2023
COVID-19 Alters Pharmaceutical Industry and API Production Dynamics
COVID-19 Exposes US Pharmaceutical Makers to Risk of Supply Shortages, Driving the Need to Revamp Domestic Industry Structure
Pandemic Leads US to Focus on Stockpiling & Localized Manufacturing to Rectify Supply Chain Flaws
EXHIBIT 2: Percentage Breakdown of API Manufacturing Facilities by Country for Drug Production in the US: 2021
Revamping Local Production Capacity
Knock-on Effect of COVID-19 on API Availability Incites Players to Reconfigure Supply Chain
COVID-19 Pandemic: A Wake-Up Call for API Seekers to Mitigate Supply Risks
Short-Term Strategies
Long-Term Strategies
Unprecedented Global Push to Expedite COVID-19 Vaccine Development to Spur Demand for APIs
EXHIBIT 3: Global Percentage of Individuals Vaccinated by Geographic Region for 2020 through 2025
EXHIBIT 4: Number of CMO Sites for Vaccine Production in Select Countries: 2020
Competition
EXHIBIT 5: Active Pharmaceutical Ingredients (API) Competitor Market Share Scenario Worldwide (in %): 2022E
Competitive Market Presence - Strong/Active/Niche/Trivial for 266 Players Worldwide in 2022 (E)
Active Pharmaceutical Ingredients: A Prelude
Global Active Pharmaceutical Ingredients Market Set to Witness Rapid Growth
Regional Landscape
North America Dominates the Global API Market
US CDMOs to Gain from Mounting Concerns Over Excess Reliance On Chinese APIs
China Continues to Remain a Major Hub
COVID-19 Brings Europe’s High Reliance on APIs Sourced from Outside under Spotlight
India Strives to Increase API Production to Attain Self Reliance in Pharmaceutical Production
EXHIBIT 6: Domestic Production and Import Share of Select API/Advanced Intermediates in India: 2019
Global PE Firms to Invest Heavily in Indian Intermediate Pharma Companies
Leading Players
Recent Market Activity
World Brands
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Sustained Increase in Drug R&D Spending to Drive API Market
EXHIBIT 7: Pharmaceutical R&D Spending Worldwide (USD Billion): 2015-2025
Increased API Sourcing Creates the need for More Scrutiny of Suppliers for Best Quality Products
Preference for Specialized CDMO Contractors on the Rise
Strong Rise in Pharmaceutical Sales to Drive Demand
EXHIBIT 8: Global Prescription Drug Sales (In US$ Billion) for the Years 2000-2025
The AIC Approach for Faster Assessment of Viable Drug Candidates
Drug Makers Embrace Digital Technology Amidst COVID-19 Crisis
EXHIBIT 9: Digital Transformation Spending in US$ Billion in Pharma Sector: 2020 and 2027
Demand for HPAPIs on the Rise
AI Finds Growing Application in Drug Discovery and Development
Microdosing Beneficial for the Formulation of High Potency Ingredients
Growing Penetration of Generic Drugs Augments Market Prospects
EXHIBIT 10: Leading Drugs Facing Patent Expiry in the US in 2021
EXHIBIT 11: Global Generic Drugs Market Size (in $ Billion) for the Years 2016, 2019, 2020 & 2025
Increasing Interest in Biopharmaceuticals Supports Market Demand
EXHIBIT 12: Global Biologic Drugs Market Size (in US$ Billion) for the Years 2019, 2022 & 2025
Rising Number of Biologics Approvals Augurs Well
EXHIBIT 13: The U.S FDA Biologic NME Approvals for Years 2016 through 2021
EXHIBIT 14: Sponsor Market Cap for the FDA-Approved Biologic FDA NMEs (2020)
Growing Biosimilars Market Create Opportunities for APIs
EXHIBIT 15: Global Biosimilars Market in US$ Billion: 2020 & 2025
Growing Attention Towards Personalized Medicine Spurs Demand for Complex API
EXHIBIT 16: Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025
Increasing Sales of OTC Drugs Presents an Opportunity for APIs
EXHIBIT 17: Global OTC Drugs Market Breakdown by Product (in %): 2021E
Growing Prevalence of Infectious Diseases to Spur Growth
EXHIBIT 18: Infectious Diseases Remain Major Cause of Death in Under Developed Regions: Breakdown of Leading Causes of Death in Sub-Saharan Africa (in %)
EXHIBIT 19: Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
Rising Incidence of Cancer & Need to Reduce Cancer-Related Mortality Spell Increased Demand
EXHIBIT 20: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
EXHIBIT 21: Global Breakdown of Total Number of Cancer Cases by Type: 2020
Increasing Prevalence of Chronic Disorders Fuels Market Growth
EXHIBIT 22: World Diabetes and Population Statistics (2019, 2030 & 2045)
Rising Incidence of Cardiovascular Diseases Revs Up Opportunities
EXHIBIT 23: Hypertension Prevalence (%) Worldwide by Region in Male and Females Aged 25+ Years
EXHIBIT 24: Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
Upsurge in ANDA Approvals Bodes Well
Aging Population & Increasing Burden of Chronic Diseases Spurs Pharma Product Sales, Driving Market Growth
EXHIBIT 25: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
Novel Technology for Continuous Manufacturing of APIs
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Active Pharmaceutical Ingredients (API) Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027
TABLE 2: World Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 3: World Historic Review for Active Pharmaceutical Ingredients (API) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 4: World 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027
TABLE 5: World Recent Past, Current & Future Analysis for Innovative by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 6: World Historic Review for Innovative by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 7: World 15-Year Perspective for Innovative by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 8: World Recent Past, Current & Future Analysis for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 9: World Historic Review for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 10: World 15-Year Perspective for Generic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 11: World Recent Past, Current & Future Analysis for Synthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 12: World Historic Review for Synthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 13: World 15-Year Perspective for Synthetic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 14: World Recent Past, Current & Future Analysis for Biotech by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 15: World Historic Review for Biotech by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 16: World 15-Year Perspective for Biotech by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 17: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 18: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 19: World 15-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 20: World Recent Past, Current & Future Analysis for Endocrinology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 21: World Historic Review for Endocrinology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 22: World 15-Year Perspective for Endocrinology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 23: World Recent Past, Current & Future Analysis for CNS & Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 24: World Historic Review for CNS & Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 25: World 15-Year Perspective for CNS & Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 26: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 27: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 28: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 29: World Recent Past, Current & Future Analysis for Gastroenterology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 30: World Historic Review for Gastroenterology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 31: World 15-Year Perspective for Gastroenterology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 32: World Recent Past, Current & Future Analysis for Orthopedic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 33: World Historic Review for Orthopedic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 34: World 15-Year Perspective for Orthopedic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
TABLE 35: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 36: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 37: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
Active Pharmaceutical Ingredients (API) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
Market Analytics
TABLE 38: USA Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 39: USA Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 40: USA 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027
TABLE 41: USA Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 42: USA Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 43: USA 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027
TABLE 44: USA Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 45: USA Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 46: USA 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027
CANADA
TABLE 47: Canada Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 48: Canada Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 49: Canada 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027
TABLE 50: Canada Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 51: Canada Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 52: Canada 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027
TABLE 53: Canada Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 54: Canada Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 55: Canada 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027
JAPAN
TABLE 56: Japan Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 57: Japan Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 58: Japan 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027
TABLE 59: Japan Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 60: Japan Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 61: Japan 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027
TABLE 62: Japan Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 63: Japan Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 64: Japan 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027
CHINA
Active Pharmaceutical Ingredients (API) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
Market Analytics
TABLE 65: China Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 66: China Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 67: China 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027
TABLE 68: China Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 69: China Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 70: China 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027
TABLE 71: China Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 72: China Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 73: China 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027
EUROPE
Active Pharmaceutical Ingredients (API) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
Market Analytics
TABLE 74: Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
TABLE 75: Europe Historic Review for Active Pharmaceutical Ingredients (API) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 76: Europe 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027
TABLE 77: Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 78: Europe Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 79: Europe 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027
TABLE 80: Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 81: Europe Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 82: Europe 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027
TABLE 83: Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 84: Europe Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 85: Europe 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027
FRANCE
TABLE 86: France Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 87: France Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 88: France 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027
TABLE 89: France Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 90: France Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 91: France 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027
TABLE 92: France Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 93: France Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 94: France 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027
GERMANY
TABLE 95: Germany Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 96: Germany Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 97: Germany 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027
TABLE 98: Germany Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 99: Germany Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 100: Germany 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027
TABLE 101: Germany Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 102: Germany Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 103: Germany 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027
ITALY
TABLE 104: Italy Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 105: Italy Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 106: Italy 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027
TABLE 107: Italy Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 108: Italy Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 109: Italy 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027
TABLE 110: Italy Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 111: Italy Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 112: Italy 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027
UNITED KINGDOM
TABLE 113: UK Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 114: UK Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 115: UK 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027
TABLE 116: UK Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 117: UK Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 118: UK 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027
TABLE 119: UK Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 120: UK Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 121: UK 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027
REST OF EUROPE
TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 123: Rest of Europe Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 124: Rest of Europe 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027
TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 126: Rest of Europe Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 127: Rest of Europe 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027
TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 129: Rest of Europe Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 130: Rest of Europe 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027
ASIA-PACIFIC
Active Pharmaceutical Ingredients (API) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Market Analytics
TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 132: Asia-Pacific Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 133: Asia-Pacific 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027
TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 135: Asia-Pacific Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 136: Asia-Pacific 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027
TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 138: Asia-Pacific Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 139: Asia-Pacific 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027
REST OF WORLD
TABLE 140: Rest of World Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 141: Rest of World Historic Review for Active Pharmaceutical Ingredients (API) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 142: Rest of World 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2012, 2021 & 2027
TABLE 143: Rest of World Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 144: Rest of World Historic Review for Active Pharmaceutical Ingredients (API) by Synthesis - Synthetic and Biotech Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 145: Rest of World 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Synthesis - Percentage Breakdown of Value Sales for Synthetic and Biotech for the Years 2012, 2021 & 2027
TABLE 146: Rest of World Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
TABLE 147: Rest of World Historic Review for Active Pharmaceutical Ingredients (API) by Application - Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
TABLE 148: Rest of World 15-Year Perspective for Active Pharmaceutical Ingredients (API) by Application - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic and Other Applications for the Years 2012, 2021 & 2027
IV. COMPETITION
Total Companies Profiled: 266

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings